Clinical characteristics of patient cohort
| Patient characteristics . | N = 6 . |
|---|---|
| Age, mean (SD) | 50.7 (12.3) |
| Female sex | 6 (100%) |
| Diagnosis | |
| Breast cancer, HR+ HER2− | 5 (83%) |
| Ovarian cancer | 1 (17%) |
| Stage | |
| I–III | 0 (0%) |
| IV | 6 (100%) |
| Treatment | |
| Ribociclib + Anti–PD-1 | 1 (17%) |
| Ribociclib + Anti–PD-1 + Fulvestrant | 5 (83%) |
| Best overall response | |
| Complete or partial response | 0 (0%) |
| Stable disease <6 mo | 3 (50%) |
| Progressive disease | 3 (50%) |
| Hepatotoxicity | |
| Grade 3 | 3 (50%) |
| Grade 2 | 2 (33%) |
| Grade 1 | 0 (0%) |
| None | 1 (17%) |
| Patient characteristics . | N = 6 . |
|---|---|
| Age, mean (SD) | 50.7 (12.3) |
| Female sex | 6 (100%) |
| Diagnosis | |
| Breast cancer, HR+ HER2− | 5 (83%) |
| Ovarian cancer | 1 (17%) |
| Stage | |
| I–III | 0 (0%) |
| IV | 6 (100%) |
| Treatment | |
| Ribociclib + Anti–PD-1 | 1 (17%) |
| Ribociclib + Anti–PD-1 + Fulvestrant | 5 (83%) |
| Best overall response | |
| Complete or partial response | 0 (0%) |
| Stable disease <6 mo | 3 (50%) |
| Progressive disease | 3 (50%) |
| Hepatotoxicity | |
| Grade 3 | 3 (50%) |
| Grade 2 | 2 (33%) |
| Grade 1 | 0 (0%) |
| None | 1 (17%) |